495 related articles for article (PubMed ID: 11758562)
1. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
Burshtein S
Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
[No Abstract] [Full Text] [Related]
2. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
3. Overview of the Hatch-Waxman Act and its impact on the drug development process.
Mossinghoff GJ
Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
[No Abstract] [Full Text] [Related]
4. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
Furrow ME
Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
[No Abstract] [Full Text] [Related]
5. Amendments to the Canadian Patent Act to address drug access: is help on the way?
Penner MD; Narayanan P
Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
[No Abstract] [Full Text] [Related]
6. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
Silbermann JM
J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
[No Abstract] [Full Text] [Related]
7. Intellectual property. Drug patents at the Supreme Court.
Hemphill CS; Sampat B
Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
[No Abstract] [Full Text] [Related]
8. Supreme Court rules against drug patent "evergreening".
Kondro W
CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081
[No Abstract] [Full Text] [Related]
9. Intellectual property. Challenges to India's pharmaceutical patent laws.
Sampat BN; Shadlen KC; Amin TM
Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
[No Abstract] [Full Text] [Related]
10. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
11. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
12. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
Hemphill Kraus EJ
N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
[No Abstract] [Full Text] [Related]
13. Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS
N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
[No Abstract] [Full Text] [Related]
14. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
15. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
16. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
Ritter M; Tempesta J; Ragusa P
Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
[No Abstract] [Full Text] [Related]
17. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
Lexchin J
Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
[TBL] [Abstract][Full Text] [Related]
18. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
Teitelbaum R; Cohen M
Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
[No Abstract] [Full Text] [Related]
19. Taking TRIPS to India--Novartis, patent law, and access to medicines.
Mueller JM
N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
[No Abstract] [Full Text] [Related]
20. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.
Tancer RS
Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
